| IMMUTEP LTD ADRS II/10 |
| USA |
| Gesundheit |
| US45257L1089 / A2H8YL |
| YP1A (Frankfurt) / IMMP (NASDAQ) |
| FRA:YP1A, ETR:YP1A, YP1A:GR, NASDAQ:IMMP |
| - |
| https://www.immutep.com/ |
|
Immutep Limited Sponsored ADR represents shares in Immutep Limited, an Australia-based late-stage biotechnology company specializing in Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. The company's lea..
>Volltext.. |
| 38.41 Mio. EUR |
| -17.51 Mio. EUR |
| 2.29 Mio. EUR |
| -47.69 Mio. EUR |
| -46.39 Mio. EUR |
| -0.32 EUR |
| 0.69 Mio. EUR |
| 41.54 Mio. EUR |
| -33.63 Mio. EUR |
| 2.11 |
| - |
| -87.22% |
| - |
| - |
| - |
| - |
| IMMUTEP ADR, IMMUTEP |
| 08.04.26 |
|